US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
US6960662B2
(en)
*
|
2000-08-04 |
2005-11-01 |
Warner-Lambert Company |
Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
|
AU2001298008A1
(en)
*
|
2000-08-04 |
2003-04-07 |
Warner-Lambert Company |
Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido (2,3-d)pyrimidin-7-ones
|
KR100639772B1
(en)
*
|
2001-02-12 |
2006-10-30 |
에프. 호프만-라 로슈 아게 |
6-substituted pyrido-pyrimidines
|
WO2002068419A1
(en)
|
2001-02-26 |
2002-09-06 |
Tanabe Seiyaku Co., Ltd. |
Pyridopyrimidine or naphthyridine derivative
|
US20030100572A1
(en)
*
|
2001-06-21 |
2003-05-29 |
Ariad Pharmaceuticals,Inc. |
Novel pyridopyrimidones and uses thereof
|
US20050154046A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Longgui Wang |
Methods of treating an inflammatory-related disease
|
GEP20063909B
(en)
|
2002-01-22 |
2006-08-25 |
Warner Lambert Co |
2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
|
ATE374201T1
(en)
*
|
2002-08-06 |
2007-10-15 |
Hoffmann La Roche |
6-ALKOXYPYRIDOPYRIMIDINES AS INHIBITORS OF P-38 MAP KINASE
|
US7129351B2
(en)
|
2002-11-04 |
2006-10-31 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
US7759336B2
(en)
|
2002-12-10 |
2010-07-20 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compounds and medicinal use thereof
|
WO2004089955A1
(en)
|
2003-04-10 |
2004-10-21 |
F.Hoffmann-La Roche Ag |
Pyrimido compounds
|
JP4053073B2
(en)
|
2003-07-11 |
2008-02-27 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
Isethionate, a selective CDK4 inhibitor
|
PL2256106T3
(en)
|
2003-07-22 |
2015-08-31 |
Astex Therapeutics Ltd |
3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
AU2004261250B2
(en)
|
2003-07-29 |
2009-02-26 |
Xenon Pharmaceuticals Inc. |
Pyridyl derivatives and their use as therapeutic agents
|
DK1685131T3
(en)
*
|
2003-11-13 |
2007-07-09 |
Hoffmann La Roche |
Hydroxyalkyl-substituted pyrido-7-pyrimidin-7-ones
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
ES2424642T3
(en)
*
|
2004-02-14 |
2013-10-07 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
BRPI0507852A
(en)
*
|
2004-02-18 |
2007-07-10 |
Warner Lambert Co |
2- (pyridin-3-ylamino) -pyrido [2,3-d] pyrimidin-7-ones
|
BRPI0509580A
(en)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
signal transduction inhibitor combinations
|
SI1761528T1
(en)
*
|
2004-06-11 |
2008-06-30 |
Japan Tobacco Inc |
5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO?á2,3-D?åPYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
JP2008519840A
(en)
|
2004-11-10 |
2008-06-12 |
ジェンザイム・コーポレイション |
How to treat diabetes
|
US20060142312A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Inc |
C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
US20090036435A1
(en)
*
|
2005-01-21 |
2009-02-05 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
MX2007008809A
(en)
*
|
2005-01-21 |
2007-09-07 |
Astex Therapeutics Ltd |
Combinations of pyrazole kinase inhibitors and further antitumor agents.
|
CA2594474C
(en)
*
|
2005-01-21 |
2016-03-29 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
AR054425A1
(en)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
|
WO2006090853A1
(en)
|
2005-02-25 |
2006-08-31 |
Ono Pharmaceutical Co., Ltd. |
Nitrogenous heterocyclic compound and medicinal use thereof
|
PE20061193A1
(en)
*
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38
|
AR053346A1
(en)
*
|
2005-03-25 |
2007-05-02 |
Glaxo Group Ltd |
COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
|
RS54876B1
(en)
|
2005-05-10 |
2016-10-31 |
Incyte Holdings Corp |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
KR100734837B1
(en)
*
|
2005-09-16 |
2007-07-03 |
한국전자통신연구원 |
System for multimodel biometric identification and method thereof
|
WO2007036791A1
(en)
*
|
2005-09-28 |
2007-04-05 |
Ranbaxy Laboratories Limited |
Pyrido-pyridimidine derivatives useful as antiinflammatory agents
|
EP1931670B1
(en)
*
|
2005-10-07 |
2012-09-12 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of pi3k
|
EP2322523B1
(en)
*
|
2005-10-07 |
2019-01-02 |
Exelixis, Inc. |
Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
ES2546181T3
(en)
|
2006-05-09 |
2015-09-21 |
Genzyme Corporation |
Methods of treating fatty liver disease by inhibiting the synthesis of glycosphingolipids
|
RU2009108006A
(en)
*
|
2006-09-08 |
2010-10-20 |
Пфайзер Продактс Инк. (Us) |
SYNTHESIS OF 2- (PYRIDIN-2-ILAMINO) -PYRIDO [2, 3-D] PYRIMIDIN-7-ONES
|
PL2074122T3
(en)
|
2006-09-15 |
2011-10-31 |
Pfizer Prod Inc |
Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
|
BRPI0715566A2
(en)
*
|
2006-10-16 |
2013-07-02 |
Gpc Biotech Inc |
compound, prodrug, pharmaceutical composition, use of a compound, method for inhibiting cell proliferation and method for synthesizing a compound
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
WO2008150260A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Gpc Biotech, Inc. |
8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
|
EP2094698A1
(en)
*
|
2006-11-09 |
2009-09-02 |
F. Hoffmann-Roche AG |
Substituted 6-phenyl-pyrido [2,3-d]pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
MX2010003603A
(en)
|
2007-10-05 |
2010-06-02 |
Genzyme Corp |
Method of treating polycystic kidney diseases with ceramide derivatives.
|
EP2231656A1
(en)
|
2007-12-19 |
2010-09-29 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
CA2719538C
(en)
|
2008-04-07 |
2014-03-18 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
MY171866A
(en)
|
2008-07-08 |
2019-11-05 |
Incyte Holdings Corp |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
CA2731685A1
(en)
|
2008-07-28 |
2010-02-04 |
Genzyme Corporation |
Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
|
GEP20135785B
(en)
*
|
2008-08-22 |
2013-03-11 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
AU2009310352A1
(en)
*
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
JP2012504646A
(en)
*
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
Protection of the hematopoietic system against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
|
MX2011003517A
(en)
*
|
2008-10-03 |
2011-05-25 |
Genzyme Corp |
2-acylaminopropoanol-type glucosylceramide synthase inhibitors.
|
JO2885B1
(en)
*
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
US9447089B2
(en)
|
2009-04-03 |
2016-09-20 |
Plexxikon Inc. |
Compositions and uses thereof
|
ES2561216T3
(en)
|
2009-05-13 |
2016-02-25 |
The University Of North Carolina At Chapel Hill |
Cyclin-dependent kinase inhibitors and use procedures
|
WO2011025006A1
(en)
*
|
2009-08-31 |
2011-03-03 |
日本ケミファ株式会社 |
Gpr119 agonist
|
EP2486037A4
(en)
*
|
2009-10-09 |
2013-01-16 |
Afraxis Inc |
8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
|
UA105813C2
(en)
|
2009-11-06 |
2014-06-25 |
Плексікон, Інк. |
Kinase-inhibiting compounds and a pharmaceutical composition (variants)
|
US8889696B2
(en)
|
2009-12-18 |
2014-11-18 |
Temple University—Of the Commonwealth System of Higher Education |
Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
|
CN102791715B
(en)
|
2009-12-31 |
2016-04-27 |
卡洛斯三世国家癌症研究中心基金会 |
As the tricyclic compound of kinase inhibitor
|
EP2558092B1
(en)
*
|
2010-04-13 |
2018-06-27 |
Novartis AG |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
TWI510487B
(en)
|
2010-04-21 |
2015-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
WO2011156786A2
(en)
*
|
2010-06-10 |
2011-12-15 |
Afraxis, Inc. |
6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
|
EP2580320B1
(en)
|
2010-06-14 |
2018-08-01 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
KR101434841B1
(en)
|
2010-08-05 |
2014-08-29 |
템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
SI2632467T1
(en)
|
2010-10-25 |
2016-10-28 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
US9808461B2
(en)
|
2010-11-17 |
2017-11-07 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
AU2012214762B2
(en)
|
2011-02-07 |
2015-08-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
WO2012129344A1
(en)
|
2011-03-23 |
2012-09-27 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
JP2014522396A
(en)
|
2011-05-27 |
2014-09-04 |
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション |
Substituted 2-benzylidene-2H-benzo [b] [1,4] thiazin-3 (4H) -one, derivatives thereof and therapeutic use thereof
|
KR102240101B1
(en)
*
|
2012-03-14 |
2021-04-14 |
루핀 리미티드 |
Heterocyclyl compounds
|
EP2831080B1
(en)
|
2012-03-29 |
2017-03-15 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
CN107383009B
(en)
|
2012-06-13 |
2020-06-09 |
因塞特控股公司 |
Substituted tricyclic compounds as FGFR inhibitors
|
WO2014011900A2
(en)
|
2012-07-11 |
2014-01-16 |
Blueprint Medicines |
Inhibitors of the fibroblast growth factor receptor
|
CA2880764C
(en)
|
2012-08-03 |
2022-08-30 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
EP3492472A1
(en)
|
2012-08-17 |
2019-06-05 |
Concert Pharmaceuticals Inc. |
Deuterated baricitinib with improved metabolic stability as jak1 and jak2 kinase inhibitor for treating e.g. rheumatoid arthritis
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
MX363715B
(en)
*
|
2013-02-21 |
2019-03-29 |
Pfizer |
Solid forms of a selective cdk4/6 inhibitor.
|
JP6435315B2
(en)
|
2013-03-15 |
2018-12-05 |
ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. |
Highly active antineoplastic and antiproliferative agents
|
LT2968290T
(en)
|
2013-03-15 |
2019-12-10 |
G1 Therapeutics Inc |
Transient protection of normal cells during chemotherapy
|
EA201892726A1
(en)
*
|
2013-03-15 |
2019-04-30 |
Консерт Фармасьютикалс, Инк. |
DEUTERED PALBOCYCLIB
|
SG11201508328PA
(en)
|
2013-04-19 |
2015-11-27 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
CN104470921B
(en)
*
|
2013-05-17 |
2017-05-03 |
上海恒瑞医药有限公司 |
Thiophene miazines derivate, preparation method therefor, and medical application thereof
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
EP3060560A1
(en)
|
2013-10-25 |
2016-08-31 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
JP6678584B2
(en)
*
|
2013-12-20 |
2020-04-22 |
バイオメッド バレー ディスカバリーズ,インコーポレイティド |
Cancer treatment using a combination of CDK and ERK inhibitors
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
US9796701B2
(en)
|
2013-12-31 |
2017-10-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
US20150297608A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents
|
EP3148532B1
(en)
|
2014-05-28 |
2021-03-03 |
Piramal Enterprises Limited |
Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
|
TWI675028B
(en)
*
|
2014-07-24 |
2019-10-21 |
美商貝達醫藥公司 |
2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
|
WO2016015597A1
(en)
*
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
Compounds as cdk small-molecule inhibitors and uses thereof
|
US20170217962A1
(en)
*
|
2014-07-31 |
2017-08-03 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
US20170224819A1
(en)
*
|
2014-08-11 |
2017-08-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
|
US20170240543A1
(en)
*
|
2014-08-14 |
2017-08-24 |
Sun Pharmaceutical Industries Limited |
Crystalline forms of palbociclib
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
CN105111201B
(en)
*
|
2014-10-16 |
2017-01-11 |
上海页岩科技有限公司 |
5-methyl-2-(pyridinyl-2-amino)-8H-pyrido[2,3-d]pyrimidin-7-ketone compounds
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
CN105622638B
(en)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
Pyrimidine or pyridopyridine ketone compounds and its preparation method and application
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
CN105616418A
(en)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
Pharmaceutical preparation containing cyclin inhibitor, and preparation method thereof
|
EP3218005B1
(en)
|
2014-11-12 |
2023-01-04 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
CN104447743B
(en)
*
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
The preparation method of Pa Boxini
|
CN104496983B
(en)
*
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
A kind of preparation method of Pa Boxini
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
CN105732615B
(en)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk kinase inhibitors
|
WO2016107605A1
(en)
|
2014-12-31 |
2016-07-07 |
昆明积大制药股份有限公司 |
Pharmaceutical composition and preparation method therefor
|
CN104610254B
(en)
*
|
2015-01-26 |
2017-02-01 |
新发药业有限公司 |
Low-cost preparation method for palbociclib
|
CZ201589A3
(en)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Palbociclib salt solid forms
|
TWI690533B
(en)
|
2015-02-12 |
2020-04-11 |
南北兄弟藥業投資有限公司 |
Compounds as cdk small-molecule inhibitors and uses thereof
|
MA41551A
(en)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
CN107438607B
(en)
|
2015-02-20 |
2021-02-05 |
因赛特公司 |
Bicyclic heterocycles as FGFR inhibitors
|
AR104068A1
(en)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
COMBINATIONS OF A 3-KINASE PHOSFOINOSYTIDE INHIBITOR COMPOSITE AND A CDK4 / 6 INHIBITOR COMPOUND FOR CANCER TREATMENT
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
CN106795159B
(en)
*
|
2015-04-22 |
2018-12-28 |
江苏恒瑞医药股份有限公司 |
A kind of crystal form and preparation method thereof of cyclin dependent kinase inhibitor
|
TWI696617B
(en)
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
Certain protein kinase inhibitor
|
KR102601320B1
(en)
*
|
2015-05-29 |
2023-11-10 |
데이진 화-마 가부시키가이샤 |
PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
|
AU2016272881C1
(en)
*
|
2015-06-04 |
2019-10-03 |
Pfizer Inc. |
Solid dosage forms of palbociclib
|
CN104892604B
(en)
*
|
2015-06-19 |
2016-08-24 |
北京康立生医药技术开发有限公司 |
A kind of synthetic method of CDK4 inhibitor
|
CN106699785A
(en)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
2-(N-oxide pyridine-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one compound as CDK4/6 inhibitor
|
WO2017021111A1
(en)
*
|
2015-08-05 |
2017-02-09 |
Ratiopharm Gmbh |
New crystalline form and acetic acid adducts of palbociclib
|
CN105085517B
(en)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
A kind of crystal type Pa Boxini free alkali hydrate and preparation method thereof
|
CN105130986B
(en)
*
|
2015-09-30 |
2017-07-18 |
广州科擎新药开发有限公司 |
Pyrimidine or pyridopyridine ketone compounds and its application
|
HU230962B1
(en)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Salts of palbociclib
|
CN106632311B
(en)
*
|
2015-11-02 |
2021-05-18 |
上海科胜药物研发有限公司 |
Preparation method of Palbociclib crystal form A and crystal form B
|
EP3373969A4
(en)
|
2015-11-12 |
2019-08-14 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
CN105418603A
(en)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
Method for preparing high-purity palbociclib and reaction intermediate of palbociclib
|
CN106810536A
(en)
|
2015-11-30 |
2017-06-09 |
甘李药业股份有限公司 |
A kind of kinases inhibitor and preparation method thereof and medical usage
|
JP6951767B2
(en)
*
|
2015-12-13 |
2021-10-20 |
ハンジョウ イノゲート ファーマ カンパニー リミテッドHangzhou Innogate Pharma Co.,Ltd. |
Heterocyclic compounds used as anti-cancer drugs
|
CN106928219B
(en)
|
2015-12-31 |
2021-08-20 |
上海医药集团股份有限公司 |
Nitrogen-containing fused heterocyclic compound, preparation method, intermediate, composition and application
|
CN105418609B
(en)
*
|
2015-12-31 |
2017-06-23 |
山东大学 |
4 (1,2,3 triazole substituted anilinic) pyridines a pair of horses going side by side pyrimidone derivatives and preparation method and application
|
CN106967061A
(en)
*
|
2016-01-13 |
2017-07-21 |
常州方楠医药技术有限公司 |
Handkerchief wins the salt in XiLin, crystal formation and preparation method thereof
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
CN107266421B
(en)
*
|
2016-04-08 |
2020-12-04 |
正大天晴药业集团股份有限公司 |
Substituted benzimidazole derivatives
|
CN107286180B
(en)
*
|
2016-04-11 |
2019-07-02 |
上海勋和医药科技有限公司 |
Miscellaneous generation Pyridopyrimidinone derivatives are as CDK inhibitor and its application
|
WO2017185031A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
CN106336411B
(en)
*
|
2016-04-27 |
2018-03-06 |
上海医药集团股份有限公司 |
The preparation technology and purposes of CDK4/6 inhibitor Pa Boxini high-purity raw medicines
|
CN105949189B
(en)
*
|
2016-06-05 |
2017-09-22 |
童明琼 |
A kind of preparation method for being used to treat the Pa Boxini of breast cancer
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
RU2019102647A
(en)
|
2016-07-01 |
2020-08-03 |
Г1 Терапьютикс, Инк. |
PYRIMIDINE-BASED ANTIPROLIFERATING AGENTS
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
US10807978B2
(en)
|
2016-07-04 |
2020-10-20 |
Dr. Reddy's Laboratories Limited |
Process for preparation of palbociclib
|
EP3481825A1
(en)
|
2016-07-07 |
2019-05-15 |
Plantex Ltd. |
Solid state forms of palbociclib dimesylate
|
MA45920B1
(en)
|
2016-08-15 |
2021-08-31 |
Pfizer |
Pyridopyrimidinone cdk2 / 4/6 inhibitors
|
KR102466192B1
(en)
|
2016-08-23 |
2022-11-14 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Combination therapy for the treatment of hepatocellular carcinoma
|
CN110022900A
(en)
|
2016-09-08 |
2019-07-16 |
蓝图药品公司 |
The combination of fibroblast growth factor receptor 4 inhibitor and cell cycle protein dependent kinase inhibitor
|
US10710999B2
(en)
|
2016-10-07 |
2020-07-14 |
Mylan Laboratories Limited |
Polymorph of an intermediate for palbociclib synthesis
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
EP3804724B1
(en)
|
2016-10-20 |
2022-12-07 |
Pfizer Inc. |
Cdk inhibitors for treating pah
|
CN106565707B
(en)
*
|
2016-11-03 |
2019-01-04 |
杭州科巢生物科技有限公司 |
Pa Boxini novel synthesis
|
CA3041886A1
(en)
|
2016-11-08 |
2018-05-17 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
EP3541389A1
(en)
|
2016-11-16 |
2019-09-25 |
Pfizer Inc |
Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
Glycan-interacting compounds and methods of use
|
AU2017364807B2
(en)
|
2016-11-28 |
2021-05-13 |
Teijin Limited |
Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
|
US11261182B2
(en)
*
|
2016-11-28 |
2022-03-01 |
Teijin Pharma Limited |
Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
|
TWI749126B
(en)
|
2016-12-16 |
2021-12-11 |
大陸商基石藥業(蘇州)有限公司 |
Cdk4/6 inhibitors
|
IL267795B2
(en)
|
2017-01-06 |
2023-02-01 |
G1 Therapeutics Inc |
Combination therapy for the treatment of cancer
|
CN108191857B
(en)
*
|
2017-01-24 |
2020-10-23 |
晟科药业(江苏)有限公司 |
6-substituted pyrido [2,3-D ] pyrimidines as protein kinase inhibitors
|
US10729692B2
(en)
*
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
KR102583737B1
(en)
*
|
2017-03-03 |
2023-09-26 |
오클랜드 유니서비시즈 리미티드 |
FGFR Kinase Inhibitors and Pharmaceutical Uses
|
EP3589319A4
(en)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
WO2018170447A1
(en)
|
2017-03-16 |
2018-09-20 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of breast cancer
|
CN108658854A
(en)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
A kind of alkaloid compound and preparation method thereof and application as marine antifoulant
|
CN108658855A
(en)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
A kind of nitrogenous dicyclic compound and its preparation method and application
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
AR111960A1
(en)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
|
CN110799191B
(en)
|
2017-06-16 |
2023-05-26 |
贝塔制药有限公司 |
Pharmaceutical formulations of N- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide and salts thereof
|
AU2018291026B2
(en)
|
2017-06-29 |
2022-09-01 |
G1 Therapeutics, Inc. |
Morphic forms of GIT38 and methods of manufacture thereof
|
EA036060B1
(en)
*
|
2017-07-17 |
2020-09-21 |
Пфайзер Инк. |
Pyridopyrimdinone cdk2/4/6 inhibitors
|
EA202090402A1
(en)
|
2017-07-28 |
2020-05-19 |
Синтон Б.В. |
PHARMACEUTICAL COMPOSITION CONTAINING PALBOCYCLIB
|
CN109384767B
(en)
*
|
2017-08-08 |
2020-05-05 |
江苏恒瑞医药股份有限公司 |
Preparation method and intermediate of pyridopyrimidine derivative
|
WO2019043504A1
(en)
|
2017-08-31 |
2019-03-07 |
Novartis Ag |
Methods of selecting a treatment for cancer patients
|
CN107488175A
(en)
*
|
2017-09-04 |
2017-12-19 |
上海微巨实业有限公司 |
A kind of pa wins the preparation method of XiLin key intermediate
|
EP3695408A4
(en)
|
2017-10-02 |
2021-12-15 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
BR112020012635A2
(en)
|
2017-12-22 |
2020-12-01 |
Ravenna Pharmaceuticals, Inc. |
aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
CN108586452A
(en)
*
|
2018-01-12 |
2018-09-28 |
重庆市碚圣医药科技股份有限公司 |
A kind of synthetic method of Pa Boxini intermediates
|
BR112020015405A2
(en)
|
2018-01-29 |
2020-12-08 |
Beta Pharma, Inc. |
2H-INDAZOL COMPOUNDS AS CDK4 AND CDK6 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, THEIR THERAPEUTIC USES AND PREPARATION METHODS
|
CN108218861B
(en)
*
|
2018-02-05 |
2019-07-23 |
黑龙江中医药大学 |
A kind of drug and preparation method thereof preventing and treating diabetes
|
WO2019157020A1
(en)
|
2018-02-06 |
2019-08-15 |
The Board Of Trustees Of The University Of Illinois |
Substituted benzothiophene analogs as selective estrogen receptor degraders
|
WO2019166928A1
(en)
|
2018-02-27 |
2019-09-06 |
Pfizer Inc. |
Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
|
WO2019168847A1
(en)
|
2018-02-27 |
2019-09-06 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
CA3099116A1
(en)
|
2018-05-04 |
2019-11-07 |
Incyte Corporation |
Salts of an fgfr inhibitor
|
AU2019262195B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Solid forms of an FGFR inhibitor and processes for preparing the same
|
WO2019220253A1
(en)
|
2018-05-14 |
2019-11-21 |
Pfizer Inc. |
Oral solution formulation
|
EP3810610A1
(en)
|
2018-05-18 |
2021-04-28 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
SI3802529T1
(en)
|
2018-05-24 |
2024-03-29 |
Synthon B.V. |
A process for making palbociclib
|
KR20210049090A
(en)
|
2018-07-05 |
2021-05-04 |
인사이트 코포레이션 |
Pyrazine derivatives fused as A2A/A2B inhibitors
|
WO2020023297A1
(en)
|
2018-07-23 |
2020-01-30 |
Genentech, Inc. |
Methods of treating cancer with pi3k inhibitor, gdc-0077
|
CN112839657A
(en)
|
2018-08-24 |
2021-05-25 |
G1治疗公司 |
Improved synthesis of 1, 4-diazaspiro [5.5] undecan-3-ones
|
JP6952747B2
(en)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
Combination of TGFβ inhibitor and CDK inhibitor for cancer treatment
|
EP3863618A1
(en)
|
2018-10-08 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Methods of treating cancer with pi3k alpha inhibitors and metformin
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
TW202035406A
(en)
*
|
2018-12-07 |
2020-10-01 |
大陸商杭州英創醫藥科技有限公司 |
Heterocyclic compound as CDK-HDAC dual pathway inhibitor
|
CN113195000A
(en)
|
2018-12-21 |
2021-07-30 |
第一三共株式会社 |
Combination of antibody-drug conjugates and kinase inhibitors
|
AU2019413683A1
(en)
*
|
2018-12-28 |
2021-08-12 |
Spv Therapeutics Inc |
Cyclin-dependent kinase inhibitors
|
TWI829857B
(en)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
|
US20220125777A1
(en)
|
2019-02-01 |
2022-04-28 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
EA202192260A1
(en)
*
|
2019-02-15 |
2021-12-17 |
Инсайт Корпорейшн |
CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND THEIR APPLICATIONS
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
TW202100520A
(en)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
AU2020281535A1
(en)
|
2019-05-24 |
2022-01-27 |
Merck Patent Gmbh |
Combination therapies using CDK inhibitors
|
CA3141452A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
CN112010844B
(en)
*
|
2019-05-31 |
2023-07-25 |
中国药科大学 |
Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor
|
TW202112767A
(en)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
CN112094272A
(en)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
CDK kinase inhibitors
|
TW202114685A
(en)
*
|
2019-06-20 |
2021-04-16 |
大陸商江蘇恒瑞醫藥股份有限公司 |
Pharmaceutical composition and preparation method thereof
|
CN110143948B
(en)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
CDK4/6 inhibitor, pharmaceutical composition, preparation method and application thereof
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
AU2020319875A1
(en)
|
2019-08-01 |
2022-02-17 |
Incyte Corporation |
A dosing regimen for an IDO inhibitor
|
EP4013750A1
(en)
|
2019-08-14 |
2022-06-22 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
WO2021072232A1
(en)
|
2019-10-11 |
2021-04-15 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
JP2022552324A
(en)
|
2019-10-14 |
2022-12-15 |
インサイト・コーポレイション |
Bicyclic heterocycles as FGFR inhibitors
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CN112759589B
(en)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
Pyrimidopyridinones and their use
|
US11697648B2
(en)
|
2019-11-26 |
2023-07-11 |
Theravance Biopharma R&D Ip, Llc |
Fused pyrimidine pyridinone compounds as JAK inhibitors
|
TW202133857A
(en)
|
2019-12-03 |
2021-09-16 |
美商建南德克公司 |
Combination therapies for treatment of breast cancer
|
KR20220131900A
(en)
|
2019-12-04 |
2022-09-29 |
인사이트 코포레이션 |
Derivatives of FGFR inhibitors
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
CA3164619A1
(en)
*
|
2019-12-16 |
2021-06-24 |
Lunella Biotech, Inc. |
Selective cdk4/6 inhibitor cancer therapeutics
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
TW202146017A
(en)
|
2020-03-05 |
2021-12-16 |
美商輝瑞股份有限公司 |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
KR20230017165A
(en)
|
2020-03-06 |
2023-02-03 |
인사이트 코포레이션 |
Combination therapy with AXL/MER and PD-1/PD-L1 inhibitors
|
JP7549032B2
(en)
|
2020-03-13 |
2024-09-10 |
プロセネスター エルエルシー |
Pyrido[2,3-d]pyrimidin-7(8H)-ones as CDK inhibitors
|
JP2021167301A
(en)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
|
PE20230825A1
(en)
|
2020-04-16 |
2023-05-19 |
Incyte Corp |
FUSIONED TRICYCLIC KRAS INHIBITORS
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
KR20230012547A
(en)
|
2020-05-19 |
2023-01-26 |
쥐원 쎄라퓨틱스, 인크. |
Cyclin-dependent kinase inhibitory compounds for the treatment of medical disorders
|
US20230132667A1
(en)
*
|
2020-05-28 |
2023-05-04 |
University Of Washington |
Drug-like molecules and methods for the therapeutic targeting of viral rna structures
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
CN113880809B
(en)
|
2020-07-03 |
2022-10-18 |
盛世泰科生物医药技术(苏州)有限公司 |
Pyrimidine derivative and preparation method and application thereof
|
JP2022019654A
(en)
|
2020-07-15 |
2022-01-27 |
ファイザー・インク |
KAT6 Inhibitor Methods and Combinations for Cancer Treatment
|
CA3189632A1
(en)
|
2020-07-20 |
2022-01-27 |
Pfizer Inc. |
Combination therapy
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
CN114246841B
(en)
*
|
2020-09-24 |
2024-02-02 |
南京济群医药科技股份有限公司 |
Composition and medicine of isethionic acid piperdine Bai Xi
|
CN114306245A
(en)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
Pharmaceutical composition of amorphous solid dispersion and preparation method thereof
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
CN112569361B
(en)
*
|
2020-12-30 |
2023-01-10 |
扬子江药业集团上海海尼药业有限公司 |
Piperazine Bai Xili dry suspension composition and preparation method thereof
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
US12065494B2
(en)
|
2021-04-12 |
2024-08-20 |
Incyte Corporation |
Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
|
JP2024522189A
(en)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Tricyclic Heterocycles as FGFR Inhibitors
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
TW202317565A
(en)
|
2021-07-07 |
2023-05-01 |
美商英塞特公司 |
Tricyclic compounds as inhibitors of kras
|
US20230114765A1
(en)
|
2021-07-14 |
2023-04-13 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
US20230022525A1
(en)
|
2021-07-26 |
2023-01-26 |
Celcuity Inc. |
Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
|
US20230174555A1
(en)
|
2021-08-31 |
2023-06-08 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
CN113683612B
(en)
*
|
2021-09-07 |
2022-06-17 |
山东铂源药业股份有限公司 |
Preparation method of palbociclib
|
CN118119393A
(en)
*
|
2021-09-14 |
2024-05-31 |
甘李药业股份有限公司 |
Medical application of CDK4/6 inhibitor
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
IL312114A
(en)
|
2021-10-14 |
2024-06-01 |
Incyte Corp |
Quinoline compounds as inhibitors of kras
|
MX2024006113A
(en)
|
2021-11-22 |
2024-07-29 |
Incyte Corp |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor.
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
IL313422A
(en)
|
2021-12-10 |
2024-08-01 |
Lilly Co Eli |
Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
AR128043A1
(en)
|
2021-12-22 |
2024-03-20 |
Incyte Corp |
SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR THEIR PREPARATION
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
TW202341982A
(en)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Cdk2 inhibitors and use thereof
|
CN114456180B
(en)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
Compounds and pharmaceutical formulations for the treatment and/or prophylaxis of malignant tumors and use thereof
|
TW202342023A
(en)
|
2022-03-07 |
2023-11-01 |
美商英塞特公司 |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
HUP2200147A1
(en)
*
|
2022-05-10 |
2023-11-28 |
Egyt Gyogyszervegyeszeti Gyar |
Pharmaceutical composition comprising palbociclib and letrozole
|
TW202413359A
(en)
|
2022-06-22 |
2024-04-01 |
美商英塞特公司 |
Bicyclic amine cdk12 inhibitors
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
EP4302755A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
CN117430597A
(en)
*
|
2022-07-14 |
2024-01-23 |
浙江同源康医药股份有限公司 |
Compounds useful as CDK4 kinase inhibitors and uses thereof
|
WO2024023703A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
|
WO2024049926A1
(en)
|
2022-08-31 |
2024-03-07 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
WO2024097206A1
(en)
|
2022-11-02 |
2024-05-10 |
Petra Pharma Corporation |
Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
|
WO2024100236A1
(en)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Combination therapies for the treatment of cancer
|
WO2024125581A2
(en)
*
|
2022-12-16 |
2024-06-20 |
上海岸阔医药科技有限公司 |
Compound and use thereof
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|